<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR941020-2-00047</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=81 g=1 f=1 --> Subpart P_Quality Assurance for Moderate or High Complexity  <!-- PJG 0012 frnewline --> Testing, or Both  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> We have determined that ASHI's requirements are equal  <!-- PJG 0012 frnewline --> to the CLIA requirements of this subpart. ASHI has edited,  <!-- PJG 0012 frnewline --> rewritten, and amplified its checklist requirements on  <!-- PJG 0012 frnewline --> quality assurance to equate to the CLIA regulation  <!-- PJG 0012 frnewline --> requirements.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> Subpart Q_Inspections  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ASHI has made revisions to the frequency of its onsite  <!-- PJG 0012 frnewline --> inspection process to a biennial basis, to equate to the  <!-- PJG 0012 frnewline --> applicable CLIA requirements at &sect;493.1777. Therefore, we  <!-- PJG 0012 frnewline --> have determined that ASHI's requirements are at least equal  <!-- PJG 0012 frnewline --> to the requirements of this subpart. The specific areas of  <!-- PJG 0012 frnewline --> the inspection process that are more stringent are:  <!-- PJG 0012 frnewline --> &bull;ASHI inspectors provide onsite proficiency testing  <!-- PJG 0012 frnewline --> samples to be processed during the inspection; and  <!-- PJG 0012 frnewline --> &bull;ASHI requires submission of a self-evaluation  <!-- PJG 0012 frnewline --> inspection for the intervening year, with an onsite  <!-- PJG 0012 frnewline --> inspection, if indicated.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> Subpart R_Enforcement Procedures for Laboratories  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ASHI meets the requirements of subpart R to the extent  <!-- PJG 0012 frnewline --> it applies to accreditation organizations. ASHI policy  <!-- PJG 0012 frnewline --> stipulates the action taken when ASHI accredited  <!-- PJG 0012 frnewline --> laboratories do not comply with its mandatory standards.  <!-- PJG 0012 frnewline --> When appropriate, ASHI will deny accreditation to a  <!-- PJG 0012 frnewline --> laboratory and report the denial to us within 30 days. ASHI  <!-- PJG 0012 frnewline --> also offers an appeals process for laboratories that have  <!-- PJG 0012 frnewline --> had a notification of denial of ASHI accreditation.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Some specific actions ASHI takes in response to non-compliance or violation of mandatory standards include:  <!-- PJG 0012 frnewline --> &bull;When an ASHI laboratory fails to maintain satisfactory  <!-- PJG 0012 frnewline --> performance in a cell exchange or PT program, the laboratory  <!-- PJG 0012 frnewline --> must either (a) successfully participate in two consecutive  <!-- PJG 0012 frnewline --> PT events (enhanced PT), submit to a reinspection and  <!-- PJG 0012 frnewline --> provide documentation of corrective actions; or (b) cease  <!-- PJG 0012 frnewline --> testing. This action is more stringent than the actions  <!-- PJG 0012 frnewline --> that we may take under subpart R. CLIA requires only the  <!-- PJG 0012 frnewline --> evaluation of a cell exchange program at the time of  <!-- PJG 0012 frnewline --> inspection. CLIA does not require PT for the specialty of  <!-- PJG 0012 frnewline --> histocompatibility. Therefore, no enhanced PT, nor  <!-- PJG 0012 frnewline --> cessation of testing due to unsatisfactory performance is  <!-- PJG 0012 frnewline --> required; and  <!-- PJG 0012 frnewline --> &bull;When ASHI determines that a serious risk of harm  <!-- PJG 0012 frnewline --> (immediate jeopardy) situation exists in a ASHI-accredited  <!-- PJG 0012 frnewline --> laboratory, the laboratory must cease testing and  <!-- PJG 0012 frnewline --> immediately correct the problem that poses the risk.  <!-- PJG 0012 frnewline --> Failure to do so will result in a revocation of  <!-- PJG 0012 frnewline --> accreditation. This action is similar to our action for  <!-- PJG 0012 frnewline --> immediate jeopardy.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            